Quick Answer
Karyopharm Therapeutics Inc. reported Stockholders Equity of -$292.93 million for the year ending 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -57.5% in Stockholders Equity from 2024 to 2025.
- This data is from Karyopharm Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $144.10 million | Q2 2014: $131.68 million | Q3 2014: $227.80 million | Q1 2015: $275.53 million | Q2 2015: $247.33 million | Q3 2015: $220.59 million | Q1 2016: $177.04 million | Q2 2016: $153.57 million | Q3 2016: $166.93 million | Q1 2017: $138.36 million | Q2 2017: $166.71 million | Q3 2017: $141.18 million | Q1 2018: $95.53 million | Q2 2018: $213.47 million | Q3 2018: $171.08 million | Q1 2019: $121.28 million | Q2 2019: $82.47 million | Q3 2019: $59.87 million | Q1 2020: $166.15 million | Q2 2020: $129.80 million | Q3 2020: $83.77 million | Q1 2021: -$39.64 million | Q2 2021: -$83.13 million | Q3 2021: -$125.98 million | Q1 2022: -$83.08 million | Q2 2022: -$116.34 million | Q3 2022: -$140.28 million | Q1 2023: -$45.17 million | Q2 2023: -$71.25 million | Q3 2023: -$100.40 million | Q1 2024: -$168.96 million | Q2 2024: -$132.14 million | Q3 2024: -$159.65 million | Q1 2025: -$205.88 million | Q2 2025: -$238.93 million | Q3 2025: -$269.26 million.
- Over the full 15 years of available data (2011 to 2025), Karyopharm Therapeutics Inc.'s Stockholders Equity has declined by 2,215.4%.
- Historical annual values: Fiscal year 2025: -$292.93 million | Fiscal year 2024: -$186.02 million | Fiscal year 2023: -$136.21 million | Fiscal year 2022: -$16.66 million | Fiscal year 2021: -$79.67 million | Fiscal year 2020: $50.55 million | Fiscal year 2019: $49.77 million | Fiscal year 2018: $183.17 million | Fiscal year 2017: $129.46 million | Fiscal year 2016: $162.24 million | Fiscal year 2015: $198.37 million | Fiscal year 2014: $206.79 million | Fiscal year 2013: $154.93 million | Fiscal year 2012: -$27.88 million | Fiscal year 2011: -$12.65 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: